Search Results

approximately 80% of the nearly 70,000 AYA patients diagnosed annually in the United States are seen and/or cared for in the community, understanding and implementing AYA care delivery in nonacademic settings is important. Recent updates to the NCCN Clinical

Background : Effective prevention and screening exists for colorectal cancer (CRC) but is underutilized, particularly in community health settings. Colonoscopy and fecal immunochemical testing (FIT) are both considered top-tier tests according

differed. In the smaller regional and community sites, cancer patient navigators (CPNs) were available for complex distress management. In the larger tertiary cancer centers where the CPN role is not part of the care model, psychologists and social workers

surveyed community hematologists/oncologists (cH/O) on their perceptions of the OlympiA trial data and the potential impact on their BRCA 1/2 testing habits in patients with early-stage BC. Methods : Between June and October 2021, practicing U.S. cH/O were

strengths. Data were used from a large community-based population of patients with cancer; therefore, the findings may better reflect FN risks in the real-world setting. The comprehensive clinical databases at KPSC allowed for detailed characterizations of

documentation of NCCN Guideline concordant and NCCN preferred treatment regimens. We assessed patterns of concordant, preferred and non-preferred treatment regimen ordering at one large multi-site community practice. Methods : We reviewed all treatment orders

study aimed to assess the prevalence of HAEs and associated health care resource utilization among patients receiving chemotherapy for ES-SCLC in the community oncology setting. Methods : Adult patients with ES-SCLC included in the Integra Connect

, community-based sample. Methods : This study uses data (collected Oct 2018–Aug 2019) from a survey that included measures of risk-management behavior, potential correlates, and information necessary to determine lifetime BC risk. Eligible participants were

following chemotherapy [1] . However, no real-world data has been published that quantifies TLS risk factors by cancer type. Methods: The Integra database of 17 community oncology accounts was queried for patients ≥18 years of age having a TLS ICD10 code

standard and may include models such as mail-order distribution (the traditional model for specialty pharmacy) or distribution from a community pharmacy. One historic feature of specialty pharmacy is the focus on diseases that are chronic and low